JBJames K. Burmester

James K. Burmester

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James K. Burmester has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 February 2015
      • Vol. 114  (1) , 16-20

    Factors that affect rate of INR decline after warfarin discontinuation.

    by James K Burmester, Richard L Berg, John R Schmelzer, Joseph J Mazza, Steven H Yale

    Despite vast literature on warfarin, optimal strategies for temporarily discontinuing and restarting warfarin have not been established. To improve warfarin discontinuation processes, we investigated known medical and genetic factors that influence stable warfarin dose to determine how well they predict the time until patients become subtherapeutic after discontinuing warfarin. This was a retrospective cohort study of patients who temporarily discontinued warfarin before an elective procedure andhad at least 2 international normalized ratio (INR) values available during the discontinuation period. Data abstracted included date of discontinuation, warfarin dose, INR values, body surface area, gender, age, indication for warfarin, current medications, eGFR, and presence of bridging therapy with heparin. DNA variants were tested in CYP2C9, VKORC1, and CYP4F2 genes. Subjects were excluded if they received vitamin K, fresh frozen plasma, or prothrombin complexes to reverse anticoagulation. Asymptotic regression models were used to approximate decline in INR during warfarin clearance. Spearman correlations and Kruskal-Wallis tests were used to characterize associations of model estimates with quantitative variables and for group comparisons, respectively. Other than the expected association with baseline INR, correlations of model parameter estimates with clinical variables were generally weak and not statistically significant. The strongest associations with slope were with serum creatinine and eGFR. There were no significant associations with CYP2C9, VKORC1, or CYP4F2 DNA variants, but there were few subjects combined in the nonwild groups for CYP2C9. Estimated slope showed moderate correlation with observed dose. Known clinical and genetic predictors of therapeutic dose were not found to be strongly associated with the slope of INR decline after warfarin discontinuation.


  • Introduction to Population Diversity and Genetic Testing

    by Michael D. Caldwell, Ingrid Glurich, Kimberly Pillsbury, James K. Burmester

    Overview of How Genetic Diversity Arises Genetic diversity arises from differences in the genome of humans. Mapping of the human genome has revealed that humans are approximately 99.9 percent identical relative to their DNA sequences, with differences occurring at the rate of one change in every 100 to 300 bases along the sequence of 3 billion bases that comprise the human genome (1, 2). These differences in coding sequences at these sites are termed single-nucleotide polymorphisms (SNPs) and are considered significant when they occur with a minimum frequency of 1 percent in a given population. Whereas genetic differences of 0.1 percent among individual humans appear negligible, occurrences of ∼10 million SNPs have been cataloged to date. These SNPs may occur in coding or noncoding regions of the genome and may affect gene expression or disease susceptibility. Whereas SNPs are estimated to account for 90 percent of all genetic variability, other genetic differences have been detected and may stem from errors during DNA replication, including copy number variations, insertions, deletions, inversions of bases, or other mutational events caused by environmental factors (3). This genetic variability contributes to genetic diversity among populations as well as its individual members. Genetic diversity has an impact on all manner of human traits from external appearance to disease susceptibility and response to pharmacological agents. To gain a greater appreciation of the magnitude of the impact that genetic diversity has on human phenotypes, it is best to begin with an exploration of its historical development in modern humans. In general, race and ethnicity, which are largely defined culturally by phenotypic traits or defined by man-made designations of geographic origin, become much less distinct at the genomic level. Mutations can occur within alleles that occupy a distinct site within a given gene or genomic region and thereby help to define traits. It is thought that population genetic diversity is largely due to a combination of allelic mutation at specific sites along the genome and the selective pressure from population segregation that occurred during the migration of humans out of Africa over a period of about 200,000 years (4). Each offspring inherits two alleles, one from each parent. Thus, if either parent is not a carrier of the wild-type allele originally encoded in the genome due to local mutations within the allele, the offspring may inherit the mutant allele and be heterozygous for a given trait. The mutation may be dominant (i.e., expressed), recessive (carried silently), or, in some cases, coexpressed. When a new mutation is associated with a beneficial trait, it is thought that positive selection occurs, allowing those carrying the beneficial allele to survive, reproduce, and pass on the trait to their offspring at a frequency dictated by its pattern of inheritance. However, the major contribution to genetic diversity occurred because of the geographical isolation that resulted from tribal resettlement following migration that produced colonies of individuals with a reduced genetic pool representative of the founders of each new colony.

  • Principles of Pharmacogenetics and Pharmacogenomics

    by Russ B. Altman, David Flockhart, David B. Goldstein, Michael D. Caldwell, Ingrid Glurich, Kimberly Pillsbury, James K. Burmester, Cristi R. King, Sharon Marsh, Terrence Blaschke, et al.

    The study of pharmacogenetics and pharmacogenomics focuses on how our genes and complex gene systems influence our response to drugs. Recent progress in clinical therapeutics has led to the discovery of new biomarkers that make it technically easier to identify groups of patients which are more or less likely to respond to individual therapies. The aim is to improve personalised medicine – not simply to prescribe the right medicine, but to deliver the right drug at the right dose at the right time. This textbook brings together leading experts to discuss the latest information on how human genetics impacts drug response phenotypes. It presents not only the basic principles of pharmacogenetics, but also clinically valuable examples that cover a broad range of specialties and therapeutic areas. This textbook is an invaluable introduction to pharmacogenetics and pharmacogenomics for health care professionals, medical students, pharmacy students, graduate students and researchers in the biosciences.


  • Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses

    by J. K. Burmester, R. L. Berg, I. Glurich, S. H. Yale, J. R. Schmelzer, M. D. Caldwell

    Warfarin is an FDA-approved oral anticoagulant for long-term prevention of thromboembolism. Substantial inter-individual variation in dosing requirements and the narrow therapeutic index of this widely-prescribed drug make safe initiation and dose stabilization challenging. Single nucleotide polymorphisms (SNPs) occurring in CYP2C9, VKORC1, and CYP4F2 genes are known to impact dose, and VKORC1 and CYP4F2 polymorphisms are associated with higher therapeutic dose requirements in our cohort. However, the most advanced regression models using personal, clinical, and genetic factors to predict individual stable dose account for only 50% to 60% of the observed variability in stable therapeutic dose in Caucasians. In this study, we used DNA sequence analysis to determine whether additional variants in CYP4F2 and VKORC1 gene coding regions contribute to variable dosing requirements among individuals for whom the actual dose was the highest relative to regression model- predicted dose. No novel DNA variants in the coding regions of these genes were identified among subjects requiring high warfarin doses, suggesting that other factors yet to be defined contribute to variability in warfarin dose requirements in this subset of our cohort.


  • DMET™ Microarray Technology for Pharmacogenomics-Based Personalized Medicine

    by James K. Burmester, Marina Sedova, Michael H. Shapero, Elaine Mansfield

    Human genome sequence variation in the form of single nucleotide polymorphisms (SNPs) as well as more complex structural variation such as insertions, duplications, and deletions underlies each individual’s response to drugs and thus the likelihood of experiencing an adverse drug reaction. The ongoing challenge of the field of pharmacogenetics is to further understand the relationship between genetic variation and differential drug responses, with the overarching goal being that this will lead to improvements in both the safety and efficacy of drugs. The Affymetrix® DMET™ Plus Premier Pack (DMET stands for Drug Metabolizing Enzymes and Transporters) enables highly multiplexed genotyping of known polymorphisms in Absorption, Distribution, Metabolism, and Elimination (ADME)-related genes on a single array. The DMET Plus Panel interrogates markers in 225 genes that have documented functional significance in phase I and phase II drug metabolism enzymes as well as drug transporters. The power of the DMET Assay has previously been demonstrated with regard to several different drugs including warfarin and clopidogrel. In a research study using an earlier four-color version of the assay, it was demonstrated that warfarin dosing can be influenced by a cytochrome P450 (CYP) 4F2 variant. Additionally, the assay has been used to demonstrate that CYP2C19 variants with decreased enzyme activity led to lower levels of the active clopidogrel metabolite, resulting in a decreased inhibition of platelets and a higher rate of cardiovascular events when compared to noncarriers of the DNA variant. Thus, highly multiplexed SNP genotyping focused on ADME-related polymorphisms should enable research into development of safer drugs with greater efficacy.


  • Understanding the pharmacogenetic approach to warfarin dosing

    by Ingrid Glurich, James K. Burmester, Michael D. Caldwell

    Warfarin remains the drug of choice for long-term anticoagulation management in a variety of conditions. Despite an established role in prevention of thromboembolic events such as stroke, warfarin continues to be underutilized because of its association with serious drug-related adverse events. Lacking alternative therapeutic approaches, intensive research in the past decade has focused on making anticoagulation with warfarin safer. Much emphasis has been placed on defining factors associated with the wide individual variability in warfarin dose. Polymorphic sites in three genes, cytochrome P450 (CYP) 2C9, vitamin K 2,3 epoxide reductase complex 1 (VKORC1), and CYP4F2, have been shown to affect stable warfarin dose. An overview of the persistent issues related to warfarin therapy and our current understanding of the genetic and clinical factors affecting warfarin dosing is presented. Finally, unresolved issues in improving clinical care of warfarin patients and future directions are provided.


  • Top Cited Papers
    Open Access

    CYP4F2 genetic variant alters required warfarin dose

    by Michael D. Caldwell, Tarif Awad, Julie A. Johnson, Brian F. Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y. Langaee, Charles Eby, et al.

    Warfarin is an effective, commonly prescribed anticoagulant used to treat and prevent thrombotic events. Because of historically high rates of drug-associated adverse events, warfarin remains underprescribed. Further, interindividual variability in therapeutic dose mandates frequent monitoring until target anticoagulation is achieved. Genetic polymorphisms involved in warfarin metabolism and sensitivity have been implicated in variability of dose. Here, we describe a novel variant that influences warfarin requirements. To identify additional genetic variants that contribute to warfarin requirements, screening of DNA variants in additional genes that code for drug-metabolizing enzymes and drug transport proteins was undertaken using the Affymetrix drug-metabolizing enzymes and transporters panel. A DNA variant (rs2108622; V433M) in cytochrome P450 4F2 (CYP4F2) was associated with warfarin dose in 3 independent white cohorts of patients stabilized on warfarin representing diverse geographic regions in the United States and accounted for a difference in warfarin dose of approximately 1 mg/day between CC and TT subjects. Genetic variation of CYP4F2 was associated with a clinically relevant effect on warfarin requirement.


  • Open Access

    Lack of evidence of WNT3A as a candidate gene for congenital vertebral malformations

    by Nader Ghebranious, Cathleen L Raggio, Robert D Blank, Elizabeth McPherson, James K Burmester, Lynn Ivacic, Kristen Rasmussen, Jennifer Kislow, Ingrid Glurich, F Stig Jacobsen, et al.

    Background: Prior investigations have not identified a major locus for vertebral malformations, providing evidence that there is genetic heterogeneity for this condition. WNT3A has recently been identified as a negative regulator of Notch signaling and somitogenesis. Mice with mutations in Wnt3a develop caudal vertebral malformations. Because congenital vertebral malformations represent a sporadic occurrence, linkage approaches to identify genes associated with human vertebral development are not feasible. We hypothesized that WNT3A mutations might account for a subset of congenital vertebral malformations. Methods: A pilot study was performed using a cohort of patients with congenital vertebral malformations spanning the entire vertebral column was characterized. DNA sequence analysis of the WNT3A gene in these 50 patients with congenital vertebral malformations was performed. Results: A female patient of African ancestry with congenital scoliosis and a T12-L1 hemivertebrae was found to be heterozygous for a missense variant resulting in the substitution of alanine by threonine at codon 134 in highly conserved exon 3 of the WNT3A gene. This variant was found at a very low prevalence (0.35%) in a control population of 443 anonymized subjects and 1.1% in an African population. Conclusion: These data suggest that WNT3A does not contribute towards the development of congenital vertebral malformations. Factors such as phenotypic and genetic heterogeneity may underlie our inability to detect mutations in WNT3A in our patient sample.


  • Open Access

    Evaluation of Genetic Factors for Warfarin Dose Prediction

    by Michael D. Caldwell, Richard L. Berg, Kai Qi Zhang, Ingrid Glurich, John R. Schmelzer, Steven H. Yale, Humberto J. Vidaillet, James K. Burmester

    Objectives: Warfarin is a commonly prescribed anticoagulant drug used to prevent thromboses that may arise as a consequence of orthopedic and vascular surgery or underlying cardiovascular disease. Warfarin is associated with a notoriously narrow therapeutic window where small variations in dosing may result in hemorrhagic or thrombotic complications. To ultimately improve dosing of warfarin, we evaluated models for stable maintenance dose that incorporated both clinical and genetic factors.


  • Small Molecule Antagonists of the TGF-β1/TGF-β Receptor Binding Interaction

    by James K. Burmester, Sherry A. Salzman, Kai Qi Zhang, Richard A. Dart

    Excessive and inappropriate action of transforming growth factor (TGF)-β has been implicated in the pathogenesis of several disease processes, especially cancer and fibrosis. To identify antagonists of the TGF-β ligand-binding domain that may have therapeutic potential, we screened the National Cancer Institute open access chemical repository for molecules that inhibited binding of TGF-β to the type II receptor (TβRII). About 30,000 molecules were screened resulting in the identification of five structurally related molecules that reduced binding of TGF-β1 to soluble TβRII with an ED50 of approx 10 μM. The chemicals blocked inhibition of Mv1Lu cell growth by TGF-β, TGF-β-induced expression of luciferase driven by the TGF-β response element, and induction of plasminogen inhibitor mRNA detected by Northern blot. In contrast, the chemicals did not block activin-induced inhibition of cell growth. Our results identify a novel chemical group that blocks binding of TGF-β to its receptor and may result in novel treatment for disease.